Commonly known as atopic dermatitis, eczema is "the itch that rashes," says Dr. Shi, meaning that an itching sensation often occurs first followed by a visible rash that develops after scratching.

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

It's been said before and it's true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...

Please provide your email address to receive an email when new articles are posted on . The FDA will review a new drug application for roflumilast foam 0.3% to treat seborrheic dermatitis in patients ...

Seborrheic dermatitis is positively associated with a range of epithelial barrier diseases, including dermatologic, respiratory, gastrointestinal, and ocular diseases.

Seborrheic dermatitis may disrupt the skin barrier, potentially exposing patients to other epithelial barrier diseases (EBDs) across various organ systems. A large cohort study found positive ...

Seborrheic dermatitis is associated with other epithelial barrier diseases of the skin and beyond, including the respiratory, ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 receptors to enhance T cell-mediated cancer cell attack.